cbdMD's Dr. Sibyl Swift Provides Testimony To the FDA Science Board on Proper Safety Methods for CBD Products

Charlotte, North Carolina--(Newsfile Corp. - June 29, 2022) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading and most highly trusted and recognized health and wellness companies, presented testimony at the public advisory committee meeting of the Science Board to the Food and Drug Administration (FDA) held earlier in June. The Company's V.P. of Science and Regulatory Affairs, Dr. Sibyl Swift, was invited to present testimony related to the safety of the Company's products, and also set forth a sensible approach for the Agency to utilize its current resources to allow hemp extracted cannabinoids to exist as Dietary Supplements. cbdMD welcomed this unique opportunity for the Company to demonstrate its leadership and commitment to providing the highest quality hemp extracted cannabinoid Dietary Supplements as they look to provide a pathway for better product efficacy and industry-wide regulation.

A transcript of the testimony will be available in the coming weeks on the FDA's website under the heading "June 14, 2022 Meeting of the Science Board to the FDA."

"Despite the Agency's preferred approach of sticking its head in the sand and feigning ignorance of the volumes of data available on the safety and efficacy of cannabinoids, we welcomed this opportunity to speak on the issue and shed light on the well established and effective methods the FDA currently has at its disposal to safely and effectively regulate orally consumed hemp extracted cannabinoids as dietary supplements," said Dr. Sibyl Swift. "Along with our extensive safety study dossier and citizens petition filed with the FDA, we believe that continually messaging about the safety of our hemp extracted cannabinoid products, and the methods we use to unequivocally prove their safety, is vital to creating an industry founded on sound scientific principles. We know that hemp extracted cannabinoids are safe, effective, and can change the way we think about daily health and well-being, and these efforts are a solid step in the right direction."

About cbdMD, Inc.

cbdMD, Inc. is one of the leading and most highly trusted and recognized hemp-derived cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products as well as Full Spectrum products. The cbdMD brand currently includes high-quality, premium CBD products including tinctures, gummies, topicals, capsules, bath bombs, sleep aids and drink mixes. The Company's Paw CBD brand includes veterinarian-formulated pet products including tinctures, chews and topicals in varying strengths. To learn more about cbdMD and the complete line of products, please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook or visit one of the thousands of retail outlets that carry cbdMD products.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on cost reductions, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 as filed with the Securities and Exchange Commission (the "SEC") on December 17, 2021 and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

1 THC-free is defined as below the level of detection using validated scientific analytical tools.

Contacts:

cbdMD, Inc.
John Weston
Director of Investor Relations
john.weston@cbdmd.com
(704) 249-9515

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129459

info